Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

August 31, 2020

Conditions
Adverse Effect of Radiation Therapy
Interventions
DRUG

aflibercept

This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.

All Listed Sponsors
lead

Larkin Community Hospital

OTHER

NCT02586727 - Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy | Biotech Hunter | Biotech Hunter